Microalbuminuria in Type 1 Diabetes Is Associated With Enhanced Excretion of the Endocytic Multiligand Receptors Megalin and Cubilin

Kathryn M. Thrailkill, md¹ Teresa Nimmo, md¹ R. Clay Bunn, phd¹ Gael E. Cockrell¹ Cynthia S. Moreau¹ Samuel Mackintosh, phd² Ricky D. Edmondson, phd³ John L. Fowlkes, md¹

OBJECTIVE — Proteinuria is the hallmark of diabetic nephropathy; yet, glomerular histology does not fully explain mechanisms contributing to proteinuria. Our objective was to identify proteins in the urine of individuals with type 1 diabetes and microalbuminuria that might implicate a mechanistic pathway operative in proteinuria.

RESEARCH DESIGN AND METHODS — Using a GeLC/MS platform proteomics approach, we compared the urine proteome from 12 healthy nondiabetic individuals, 12 subjects with type 1 diabetes yet normal urinary albumin excretion rates, and 12 subjects with type 1 diabetes and microalbuminuria (type 1 diabetes + microalbuminuria).

RESULTS — The abundance of megalin and cubilin, two multiligand receptors expressed in kidney proximal tubule cells and involved with the reuptake of filtered albumin and megalin/ cubilin ligands, was significantly increased in type 1 diabetes + microalbuminuria urine, compared with both nonalbuminuric groups.

CONCLUSIONS — Aberrant shedding of megalin and cubilin could contribute to albuminuria in diabetes and to deficiency states of important vitamins and hormones.

Diabetes Care 32:1266-1268, 2009

xcess urinary albumin excretion (UAE) (30–299 mg/day), termed microalbuminuria, portends incipient diabetic nephropathy. Mechanisms contributing to proteinuria in diabetic nephropathy are incompletely understood but likely involve pathology within the glomerulus, including endothelial cell injury, glomerular basement membrane thickening, loss of slit diaphragm veracity, and podocytopenia (1). Additionally, in the proximal tubule (PT), decreased protein reabsorption likely occurs (1,2); data from diabetic animals suggest that

altered PT handling and diminished albumin retrieval contribute to albuminuria (3,4). Because ~70% of the urinary proteome originates from kidney or genitourinary tissues (5,6), we used the GeLC/MS platform proteomics approach to compare the urine proteome from 1) nondiabetic individuals, 2) subjects with type 1 diabetes yet normal UAE, and 3) subjects with type 1 diabetes and microalbuminuria (type 1 diabetes + microalbuminuria), so as to identify proteins that might implicate a mechanistic pathway operative in proteinuria.

From the ¹Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital Research Institute, Little Rock, Arkansas; the ²Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas; and the ³Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Corresponding author: Kathryn M. Thrailkill, thrailkillkathrynm@uams.edu.

Published ahead of print at http://care.diabetesjournals.org on 14 April 2009. DOI: 10.2337/dc09-0112.

© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons. org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

RESEARCH DESIGN AND

METHODS — This study was conducted as a subanalysis of a study described elsewhere (7); 12 of 143 originally described subjects had type 1 diabetes + microalbuminuria (UAE ≥30 mg albumin/g creatinine, herein designated as group 3). Two additional subgroups (matched to group 3 for age and sex) were identified and designated group 1: healthy, nondiabetic, nonalbuminuric subjects (n =12); and group 2: subjects with type 1 diabetes and normal UAE (<30 mg albumin/g creatinine; n = 12). Group characteristics are available in Table A1 in an online-only appendix at http://care.diabetesjournals. org/cgi/content/full/dc09-0112/DC1.

An SDS-PAGE to liquid chromatography-tandem mass spectrometry (GeLC/ MS) platform was used to compare 24-h urine samples from subjects in groups 1–3. liquid chromatography-tandem mass spectrometry allows for identification of proteins in urine; relative protein abundance was quantified by spectral counting (5,8). For each subject, a urine aliquot corresponding to 1,000 μ g urine creatinine was calculated. Within each group, these 12 aliquots were pooled into four pools (two female + two male pools of three subjects each); each pool was independently analyzed. ANOVA was used to ascertain differences between groups. Linear relationships between data were analyzed using the Pearson product moment correlation.

RESULTS — Groups 1–3 were comparable for sex, age, BMI, blood pressure, and glomerular filtration rate (Table A1 in the online appendix). Groups 2 and 3 were comparable for disease duration and displayed higher A1C and continuous glucose monitoring system glucose and lower C-peptide values compared with controls. Per study design, group 3 alone exhibited increased UAE.

Over 150 protein signatures were identified by GeLC/MS analysis to be either 1) only identified in group 3 urine or 2) present in groups 1 and 3 urine but exhibiting at least two times greater frequency, by spectral counting, in group 3

Received 20 January 2009 and accepted 31 March 2009.

DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009

compared with group 1 (P < 0.05). The most abundant proteins in all groups were albumin, uromodulin, and α -1microglobulin/bikunin precursor, respectively. Two PT endocytic receptors, megalin (i.e., LRP2) and cubilin, active in the reuptake of filtered small-molecularweight proteins (9), were among the 20 most abundant proteins in group 3 urine (see Table A2 in the online appendix) and were significantly more abundant in urine from group 3, compared with groups 1 or 2 (Table 1). Neither receptor was identified in the 20 most abundant proteins in groups 1 or 2. Megalin and cubilin form a complex on the cell surface of PT cells (9). Using data from all groups, megalin and cubilin mean spectral counts were highly correlated, consistent with evidence that they form a cellular complex and are coexcreted in urine (Table 1).

Megalin is a membrane-bound protein, and the extracellular domain can be shed from PT cells (10). Analysis of the peptide spectra generated by GeLC/MS revealed that >99% of the peptide fingerprinting covered regions of the extracellular domain. Moreover, the most COOH-terminal peptide detected in all groups extended to amino acid 4304 within the extracellular domain, suggesting that urinary megalin represents predominantly the extracellular component.

Megalin and cubilin participate in the reuptake and endocytosis by PT cells of a number of proteins including albumin. Several megalin and/or cubilin ligands were elevated in or only detected in urine from group 3 (Table 1). Analyzing data from all groups, the urinary abundance of albumin correlated with the urinary abundance of both megalin and cubilin (Table 1). Several other megalin/cubilin ligands also correlated with megalin/ cubilin abundance (Table 1).

CONCLUSIONS — Megalin is an ~600-kDa single-spanning transmembrane glycoprotein belonging to the LDL receptor family (9). This endocytic receptor is primarily expressed in polarized epithelial cells including PT cells of the kidney and is a multiligand receptor with many ligands including albumin, vitamin-binding proteins, carrier proteins, lipoproteins, hormones, and drugs (9). Cubilin is an ~460-kDa peripheral membrane glycoprotein with no transmembrane component (9). Also expressed in renal PT cells, cubilin binds several ligands in common with megalin including albumin, vitamin D binding protein,

Т	hrailkill	and	Associates
L	III ALLIVILL	unu	113300111103

able 1—Comparisons and correlations of megalin, cubilin, and their ligands in urine

Comparisons* Con				Correli	ations
2: Type 13: Type 1 diabetes +Protein/ligand1: Controldiabetesmicroalbuminuria1 vs. 21 vs. 32 vs. 3Megalin vs. ligand	+ 1 vs. 2	1 vs. 3	2 vs. 3	Megalin vs. ligand	Cubilin vs. ligand
Megalin 5.63 ± 1.60 3.13 ± 3.94 20.13 ± 9.19 NS <0.05 <0.001 —	SN	<0.05	< 0.001	I	R = 0.88; P < 0.0001
Cubilin 2.63 ± 3.78 1.50 ± 2.98 20.13 ± 15.8 NS <0.01 <0.001 R = 0.88; P < 0.0001	SN	< 0.01	< 0.001	R = 0.88; P < 0.0001	
Angiotensinogen ND ND 0.25 ± 0.71 — — — —					
TBG ND ND 0.63 ± 0.92 — … <th…< th=""> … …</th…<>					
IGF2R ND ND 1.13 ± 1.55					
APOA1 ND ND 2.0 ± 1.77					
Transthyretin ND ND 3.38 ± 1.77 — … <td> </td> <td> </td> <td> </td> <td> </td> <td> </td>					
VDBP 0.5 ± 0.76 1.13 ± 1.46 3.63 ± 1.69 NS <0.01 <0.05 $R = 0.433; P = 0.04$	SN	< 0.01	< 0.05	R = 0.433; P = 0.04	R = 0.399; P = 0.05
Clusterin ND 1.13 ± 1.55 4.88 ± 3.04 <- <0.05			< 0.05		I
RBP4 2.25 ± 2.05 2.25 ± 2.77 8.88 ± 5.25 NS <0.05 <0.01 R = 0.444; P = 0.03	SN	< 0.05	< 0.01	R = 0.444; P = 0.03	SN
EGF 8.75 ± 6.39 7.38 ± 1.77 22.0 ± 10.04 NS <0.05 <0.05 $R = 0.663; P < 0.001$	SN	< 0.05	< 0.05	R = 0.663; P < 0.001	R = 0.682; P < 0.001
Serotransferrin 8.5 ± 8.72 13.88 ± 13.62 90.38 ± 45.14 NS <0.001 <0.01 $R = 0.791; P < 0.001$	SN	< 0.001	< 0.01	R = 0.791; P < 0.001	R = 0.574; P < 0.01
Albumin 213.4 ± 83.7 244.8 ± 168.7 515.5 ± 140.9 NS <0.01 <0.05 R = 0.748; P < 0.001	SN	< 0.01	< 0.05	R = 0.748; P < 0.001	R = 0.614; P = 0.001

Megalin and cubilin in type 1 diabetes

transferring, and lipoproteins (9). Together, these receptors are responsible for the tubular clearance of most filtered proteins. In fact, over ~95% of filtered albumin is reabsorbed in the PT primarily via the megalin-cubilin complex (2). Because megalin and cubilin are involved in reuptake of albumin and smaller proteins from the glomerular filtrate, diminished functioning of these receptors in diabetes could contribute to proteinuria. Animal and clinical investigations support this hypothesis by demonstrating selective proteinuria in conditions of megalin or cubilin loss of function (11–13).

Studies have shown that LRP family members, including megalin, are shed from cell surfaces by matrix metalloproteinases (10). Matrix metalloproteinase activity is elevated in type 1 diabetes urine (7), and matrix metalloproteinase expression is altered in the diabetic kidney (14). Thus, enhanced matrix metalloproteinase activity in the parenchyma and/or tubular lumen of the diabetic kidney might result in shedding of the megalin/cubilin complex from PT cell surfaces. Secondary to megalin and cubilin loss, isolated deficiencies of certain small-molecularweight proteins and their ligands (i.e., vitamins) would be predicted.

Certain study limitations exist. This study was a sub-analysis of a preexisting dataset and was not intended to predict disease progression, but, rather, to identify proteins that might infer a mechanistic pathway operative in diabetic nephropathy. Confirmation that "megalin-uria" or "cubilin-uria" correlates with or predicts microalbuminuria will require measurement of megalin and cubilin in individual specimens from a larger prospective cohort. At present, however, there are no immunometric assays for megalin or cubilin to allow for quantitative assessment.

Acknowledgments— This work was supported by grants from the National Institutes of Health to K.M.T. (R01-DK62999), to the UAMS General Clinical Research Center (M01 RR14288), and to the Arkansas Children's Hospital Research Institute (C06RR16517). No potential conflicts of interest relevant to this article were reported.

References

- Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008; 74:22–36
- Hryciw DH, Lee EM, Pollock CA, Poronnik P. Molecular changes in proximal tubule function in diabetes mellitus. Clin Exp Pharmacol Physiol 2004;31:372–379
- 3. Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D: Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2008;20:489–494
- Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM. Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008;295:F1589–F1600
- Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, Schanstra JP. Urine in clinical proteomics. Mol Cell Proteomics 2008;7:1850–1862
- 6. Thongboonkerd V, Malasit P. Renal and urinary proteomics: current applications and challenges. Proteomics 2005;5:1033-1042
- 7. Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN,

Frindik JP, Kemp SF, Fowlkes JL. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 2007;30:2321– 2326

- Liu H, Sadygov RG, Yates JR 3rd: A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76:4193– 4201
- Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002;3:258–268
- Biemesderfer D. Regulated intramembrane proteolysis of megalin: linking urinary protein and gene regulation in proximal tubule? Kidney Int 2006;69:1717–1721
- Kantarci S, Al-Gazali L, Hill RS, Donnai D, Black GC, Bieth E, Chassaing N, Lacombe D, Devriendt K, Teebi A, Loscertales M, Robson C, Liu T, MacLaughlin DT, Noonan KM, Russell MK, Walsh CA, Donahoe PK, Pober BR. Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet 2007;39:957–959
- Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C, Aucouturier P, Moskaug JO, Otto A, Christensen EI, Willnow TE. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 1999;155:1361– 1370
- Aminoff M, Carter JE, Chadwick RB, Johnson C, Grasbeck R, Abdelaal MA, Broch H, Jenner LB, Verroust PJ, Moestrup SK, de la Chapelle A, Krahe R. Mutations in CUBN, encoding the intrinsic factor-vitamin B12 receptor, cubilin, cause hereditary megaloblastic anaemia 1. Nat Genet 1999;21:309–313
- Thrailkill KM, Clay Bunn R, Fowlkes JL. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocrine 2009;35:1–10